The overexpression of CD73 in cancer cells promoted tumor growth and decreased CD8+ T cell infiltration in immune‐competent mice, suggesting that targeting CD73 might be a promising therapeutic strategy for PDAC. This evidence concerns the gene CD8A and neoplasm.